(CercleFinance.com) – Biosynex shares suffered one of the strongest declines in the Paris market on Friday, the manufacturer of rapid diagnostic tests having unveiled annual results showing a marked deterioration in its activity and its profits.
At 2:30 p.m., the action of the Alsatian laboratory fell by 15.7% when the CAC Mid & Small index only lost 0.6%.
Biosynex reported last night an annual turnover down 49% to 196.6 million euros for the past financial year due to the decline in the Covid-19 pandemic.
The global ebb of the epidemic has considerably reduced the need for tests, whether in laboratories or pharmacies, after financial years 2020, 2021 and 2022 which had seen the company become a European leader in self-tests and post exceptional growth.
The group – which has endeavored to preserve its margins thanks to the management of its product mix – generated a gross margin of 101.6 million euros, showing a rate of 51.7%, up 1.8 point.
Its gross operating surplus (EBITDA) stood at 51.9 million euros, down 64% compared to 2021, while net income fell to 15.6 million euros from 104 million. euros in 2021.
In the first quarter of 2023, its turnover fell further by 83% to 18.7 million euros.
After a further decline in activity expected in 2023, against a backdrop of the end of the preponderance of Covid-19 products, the group expects a return to growth from 2024.
He then says he anticipates reaching a turnover of 150 million euros by 2025.